Q-omics provides the consensus-scored MGST3 profile across patient tissues and cancer cell-line models. MGST3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MGST3 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, MGST3 protein abundance shows 25,324 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, KICH, and GBM as cancer lineages where MGST3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MGST3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MGST3 survival associations across molecular data types. MGST3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MGST3 RNA expression–survival associations across cancer types. High MGST3 expression shows unfavorable associations in UVM, SCLC, ACC, LUAD, HNSC and KICH. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MGST3 RNA expression.
This table summarizes MGST3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KICH for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MGST3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MGST3 shows lower tumor expression in KICH, COAD, LUAD and LUSC and higher tumor expression in LIHC and KIRP. The KICH box plot shows higher MGST3 RNA expression in normal versus tumor tissue (log2 FC = −1.148, t-test p < 0.001).
This table shows molecular features associated with MGST3 in patient tissues and cancer cell lines. In patient samples, MGST3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, MGST3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and BLOOD_Lymphoma.
